Test ID BLOD1652 Chromogenic Factor VIII Inhibitor Bethesda Profile, Plasma
Ordering Guidance
This test is indicated for testing for FVIII inhibitors in patients being treated with the specific antibody emicizumab (Hemlibra).
This test is for detection of presence of specific inhibitors against factor VIII (FVIII). If the presence or type of inhibitor is unknown, APROL / Prolonged Clot Time Profile, Plasma or ALUPP / Lupus Anticoagulant Profile, Plasma should be ordered first.
Multiple coagulation profile tests are available. For testing that is performed with each profile, see Coagulation Profile Comparison.
Shipping Instructions
Send all vials in the same shipping container.
Specimen Required
Specimen Type: Platelet-poor plasma
Collection Container/Tube: Light-blue top (3.2% sodium citrate)
Submission Container/Tube: Plastic vials
Specimen Volume: 2 mL in 2 plastic vials, each containing 1 mL
Collection Instructions:
1. Specimen must be collected prior to factor replacement therapy.
2. If collecting sample through a port/line, be sure to waste the appropriate amount prior to collection.
3. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing.
4. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.
5. Aliquot plasma (1 mL per aliquot) into 2 separate plastic vials leaving 0.25 mL in the bottom of centrifuged vial.
6. Freeze plasma immediately (no longer than 4 hours after collection) at -20° C or ideally, at or below -40° C.
Additional Information:
1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.
2. Each coagulation assay requested should have its own vial.
Forms
1. Coagulation Patient Information (T675)
2. If not ordering electronically, complete, print, and send an Coagulation Test Request (T753) with the specimen.
Secondary ID
610420Useful For
Detecting the presence and titer of a specific factor inhibitor directed against coagulation factor VIII for patients on emicizumab (Hemlibra)
Detecting the presence and titer of an inhibitor directed against factor VIII
This test is not useful for detecting the presence of inhibitors directed against other clotting factors and will not detect the presence of lupus anticoagulants.
Profile Information
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
CH8BI | Chromogenic FVIII Inhibitor Interp | No | Yes |
CHF8 | Chromogenic FVIII, P | Yes | Yes |
CH8B | Chromogenic FVIII Inhibitor Titer,P | No | Yes |
Special Instructions
Method Name
Chromogenic
Reporting Name
Chromogenic FVIII Inhibitor ProfileSpecimen Type
Plasma Na CitSpecimen Minimum Volume
See Specimen Required
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Plasma Na Cit | Frozen | 14 days |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
IV heparin contamination | Reject |
Reference Values
CHROMOGENIC Factor VIII Activity Assay
Adults: 55.0-200.0%
Normal, full-term newborn infants or healthy premature infants usually have normal or elevated factor VIII.*
*See Pediatric Hemostasis References section in Coagulation Guidelines for Specimen Handling and Processing.
BETHESDA TITER
≤0.5 Bethesda Units
Day(s) Performed
Monday through Friday
Report Available
3 to 4 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
See Individual Test IDsCPT Code Information
CHF8-85130
CH8B-85335
CH8BI-85390-26